<DOC>
	<DOCNO>NCT02311894</DOCNO>
	<brief_summary>This Phase IV , multicenter , open-label , single-arm study somatropin ( rDNA origin ) ( Nutropin AQ v1.1 ) pre-pubertal child growth hormone deficiency ( GHD ) naïve prior recombinant human growth hormone ( rhGH ) treatment . The study design characterize immunogenicity profile somatropin ( rDNA origin ) injection administer daily subcutaneously 12 month . The clinical impact immunogenicity also assess .</brief_summary>
	<brief_title>A Post-Marketing Study Immunogenicity Somatropin ( Ribosomal Deoxyribo Nucleic Acid rDNA Origin ) Injection ( Nutropin AQ® ) Children With Growth Hormone Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Endocrine System Diseases</mesh_term>
	<mesh_term>Dwarfism , Pituitary</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<criteria>Bone age less equal ( &lt; /= ) 9 year ( female ) &lt; /= 11 year ( male ) determine Xray leave hand wrist use Greulich Pyle method obtain within 12 month prior enrollment Prepubertal ( Tanner I ) male females physical examination Diagnosis GHD ( stimulate GH less [ &lt; ] 10 nanogram per milliliter [ ng/mL ] ) two standard pharmacologic test obtain 12 month prior inform consent/assent Normal thyroid function test within 12 month prior inform consent/assent Normal complete blood count within 12 month prior inform consent/assent Documentation prior height weight measurement , height standard deviation score ( SDS ) &lt; /= 5th percentile idiopathic isolate GHD participant Any previous rhGH treatment Short stature etiologies GHD Acute critical illness uncontrolled chronic illness , opinion investigator medical monitor , would interfere participation study , interpretation data , pose risk participant safety Chronic illnesses inflammatory bowel disease , celiac disease , heart disease , diabetes Bone diseases achondroplasia hypochondroplasia , intracranial tumor , irradiation , traumatic brain injury Participants receive oral inhale chronic corticosteroid therapy ( great [ &gt; ] 3 month ) medical condition central adrenal insufficiency Participants require high ( 2 time great maintenance ) dose corticosteroids 5 day 6 month prior enrollment study Participants active malignancy condition investigator believe would pose significant hazard participant rhGH initiate Females Turner syndrome regardless GH status PraderWilli syndrome regardless GH status Born small gestational age regardless GH status Presence scoliosis require monitor Previous participation another clinical trial investigation GH , treatment growth failure , treatment biologic agent Participants close epiphysis Participants know hypersensitivity somatropin , excipients , diluent</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>14 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>